Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119678 | 0.96 | ALDH1A1 (0.57) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL11823127 | 0.89 | RAB9A (0.44) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL8154285 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL8149641 | 0.82 | ALDH1A1 (0.57) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL79080 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL1696787 | 0.82 | USP2 (0.55) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL2725729 | 0.81 | MAPT (0.59) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL20901665 | 0.81 | HRH3 (0.59) | ALDH1A1MAPTHPGDAKR1C3LMNA | |
| SCHEMBL11142367 | 0.80 | ALDH1A1 (0.74) | ALDH1A1HPGDAKR1C3TSHRSMN1; SMN2 | |
| SCHEMBL85175 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDAKR1C3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | ALDH1A1 1182/4885MAPT 22/4885HPGD 1673/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | ALDH1A1 1170/4885MAPT 24/4885HPGD 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.